Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal, Alexander Starodub, Brian D. Koh, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 18, pp. 3979-3989
Open Access | Times Cited: 16

Showing 16 citing articles:

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Kenneth K.W. To, Enming Xing, Ross C. Larue, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3043-3043
Open Access | Times Cited: 37
Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
В. Даниэльс, Jun Luo, Channing J. Paller, et al.
Cells (2024) Vol. 13, Iss. 1, pp. 104-104
Open Access | Times Cited: 6
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Amit Kumar, Luni Emdad, Paul B. Fisher, et al.
Advances in cancer research (2023), pp. 73-161
Closed Access | Times Cited: 15
State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer
Saravanan Ramesh, Preethi Selvakumar, Mohamed Yazeer Ameer, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design
Haiyang Zhong, Xinyue Wang, Shicheng Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 1, pp. 138-151
Closed Access | Times Cited: 12
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors
Sarah Gold, Ali Shilatifard
Current Opinion in Genetics & Development (2024) Vol. 86, pp. 102181-102181
Closed Access | Times Cited: 4
Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer
Nicholas Choo, Shivakumar Keerthikumar, Susanne Ramm, et al.
The Journal of Pathology (2024) Vol. 263, Iss. 2, pp. 242-256
Open Access | Times Cited: 4
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
Tianpeng Zheng, Shanglong Wang, Wukun Liu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer
Xiaolin Zhu, Chien‐Kuang Cornelia Ding, Rahul Aggarwal
Current Oncology Reports (2025)
Closed Access
Ectopic expression of testis-specific transcription elongation factor in driving cancer
Bin Zheng, Marta Iwanaszko, Shimaa Soliman, et al.
Science Advances (2025) Vol. 11, Iss. 11
Open Access
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
Ulrich M. Lauer, Ahmad Awada, S. Postel-Vinay, et al.
ESMO Open (2025) Vol. 10, Iss. 5, pp. 104499-104499
Closed Access
Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential
Ling Tang, Peng Lin, Chao Tan, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials
Alice Rossi, Francesca Zacchi, Anna Reni, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11740-11740
Open Access | Times Cited: 2
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Adel Mandl, Mark C. Markowski, Michael A. Carducci, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 3, pp. 213-228
Closed Access | Times Cited: 6
BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer
Shipra Shukla, Dan Li, Holly M. Nguyen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma
Dan Zou, Sitong Feng, Bowen Hu, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access
Page 1

Scroll to top